| Literature DB >> 32968388 |
Uzma Mahar1, Nida Anwar2, Naveena Fatima3, Jawad Hassan4, Tahir Shamsi5.
Abstract
OBJECTIVE: We performed a prospective analysis at our center to find out the most common organisms causing bacterial infections to establish pattern of antibiotic resistance, in order to combat febrile neutropenia effectively in the terms of outcome as well as cost.Entities:
Keywords: Anti-Microbial Resistance; Febrile Neutropenia; Quality Control
Year: 2020 PMID: 32968388 PMCID: PMC7501026 DOI: 10.12669/pjms.36.6.2138
Source DB: PubMed Journal: Pak J Med Sci ISSN: 1681-715X Impact factor: 1.088
Occurrence and association of gram negative organisms (n=302) in different specimens.
| Specimen | Escherichia coli N(%) | Proteus mirabilis N(%) | Klebsiella pneumoniae N(%) | Pseudomonas aeruginosa N(%) | Salmonella sp. N(%) | P-value |
|---|---|---|---|---|---|---|
| Pus C/S, N=16 | 2(12) | 1(6) | 6(38) | 7(44) | 0 | 0.000 |
| Urine C/S, N=129 | 79(61) | 2(2) | 19(15) | 29(22) | 0 | |
| Hickman Line, N=47 | 16(34) | 0 | 12(26) | 19(40) | 0 | |
| Peripheral, N=60 | 16(27) | 0 | 20(33) | 14(23) | 10(17) | |
| Throat swab C/S N=41 | 8(200 | 0 | 22(53) | 11(27) | 0 | |
| Sputum for C/S N=05 | 0 | 0 | 2(25) | 3(75) | 0 | |
| Wound Swab | 0 | 0 | 0 | 0 | 0 | |
| Nose Swab | 0 | 0 | 0 | 0 | 0 | |
| Bone marrow C/S N=04 | 0 | 0 | 1(25) | 2(50) | 1(25) |
Occurrence and association of gram positive organisms (n=101) in different specimens.
| Specimen | Streptococcus epidermidis N (%) | Staphylococcus aureus N (%) | Enterococcus Species N (%) | β Hemolytic Streptococcus Group A N (%) | P-value |
|---|---|---|---|---|---|
| Pus C/S, N=18 | 2(11) | 15(83) | 0 | 1(6) | 0.000 |
| Urine C/S, N=28 | 0 | 2(7) | 26(93) | 0 | |
| Hickman Line N=14 | 0 | 8(57) | 6(43) | 0 | |
| Peripheral, N=23 | 2(9) | 16(70) | 4(17) | 1(4) | |
| Throat Swab for C/S, N=14 | 0 | 12(86) | 0 | 2(14) | |
| Sputum for C/S, N=01 | 0 | 0 | 0 | 1(100) | |
| Wound Swab, N=01 | 0 | 1(100) | 0 | 0 | |
| Nose Swab, N=02 | 0 | 2(100) | 0 | 0 | |
| Bone Marrow C/S | 0 | 0 | 0 | 0 |
Association of resistance and sensitivity of antibiotics in isolates of gram positive organisms.
| Antibiotics | Resistance /Sensitivity | Streptococcus epidermidis N (%) | Staphylococcus aureus N (%) | Enterococcus Species N (%) | β Hemolytic Streptococcus Group A N (%) | P-value |
|---|---|---|---|---|---|---|
| Ampicillin (n=100) | R (n=78) | 0 | 53(53) | 25(25) | 0 | 0.000 |
| S (n=22) | 4(4) | 2(2) | 11(11) | 5(5) | ||
| Amox-clav (n=100) | R (n=71) | 2(2) | 44(44) | 25(25) | 0 | 0.002 |
| S (n=29) | 2(2) | 11(11) | 11(11) | 5(5) | ||
| Piperacillin- Tazobactam (n=100) | R (n=71) | 2(2) | 44(44) | 25(25) | 0 | 0.002 |
| S (n=29) | 2(2) | 11(11) | 11(11) | 5(5) | ||
| Ceftriaxone (n=100) | R (n=78) | 3(3) | 44(44) | 31(31) | 0 | 0.000 |
| S (n=22) | 1(1) | 11(11) | 5(5) | 5(5) | ||
| Vancomycin (n=96) | R (n=16) | 0 | 2(2) | 14(15) | 0 | 0.000 |
| S (n=80) | 4(4) | 50(52) | 21(22) | 5(5) | ||
| Meropenem (n=98) | R (n=68) | 2(2) | 41(41) | 25(26) | 0 | 0.004 |
| S (n=30) | 2(2) | 13(13) | 10(10) | 5(5) | ||
| Amikacin (n=92) | R (n=44) | 0 | 9(10) | 35(38) | 0 | 0.000 |
| S (n=49) | 4(4) | 44(48) | 1(1) | 0 | ||
| Ciprofloxacin (n=100) | R (n=77) | 2(2) | 42(42) | 33(33) | 0 | 0.000 |
| S (n=23) | 2(2) | 13(13) | 3(3) | 5(5) | ||
| Fosfomycin (n=98) | R (n=17) | 0 | 6(6.1) | 11(11) | 0 | 0.032 |
| S (n=81) | 4(4) | 49(50) | 23(23) | 5(5) | ||
| Neomycin (n=19) | R (n=7) | 0 | 7(37) | 0 | 0 | 0.354 |
| S (n=12) | 2(11) | 9(48) | 0 | 1(5) |
R=resistance, S= sensitivity
Association of resistance and sensitivity of antibiotics in isolates of gram negative organisms.
| Antibiotics | Resistance /Sensitivity | Escherichia colis N(%) | Proteus mirabilis N(%) | Klebsiella pneumoniae N(%) | Pseudomonas aeruginosa N(%) | Salmonella sp. N(%) | P- value |
|---|---|---|---|---|---|---|---|
| Ampicillin (n=300) | R(n=289) | 115(38) | 2(0.6) | 81(27) | 85(28) | 6(2) | 0.000 |
| S(n=11) | 5(2) | 1(0.3) | 0 | 0 | 5(1.6) | ||
| Amox-clav (n=299) | R(n=199) | 80(27) | 1(0.3) | 52(17) | 66(22) | 0 | 0.000 |
| S(n=100) | 40(13) | 2(0.6) | 29(10) | 19(6) | 10(3) | ||
| Piperacillin- tazobactam (n=301) | R(n=60) | 34(11) | 0 | 16(5) | 10(3) | 0 | 0.015 |
| S(n=241) | 86(29) | 3(0.9) | 66(22) | 75(25) | 11(4) | ||
| Ceftriaxone (n=300) | R(n=185) | 95(32) | 1(0.9) | 44(15) | 45(15) | 0 | 0.000 |
| S(n=115) | 25(8) | 2(0.6) | 37(12) | 40(13) | 11(4) | ||
| Meropenem (n=293) | R(n=50) | 16(5) | 0 | 15(5) | 19(6) | 0 | 0.215 |
| S(n=243) | 99(34) | 3(1) | 66(22) | 64(22) | 11(3) | ||
| Amikacin (n=294) | R(n=69) | 19(6) | 1(0.3) | 21(7) | 28(9) | 0 | 0.018 |
| S(n=225) | 97(33) | 2(0.6) | 60(20) | 55(18) | 11(3) | ||
| Ciprofloxacin (n=297) | R(n=135) | 87(29) | 0 | 22(7) | 18(6) | 8(2) | 0.000 |
| S(n=162) | 33(11) | 3(1) | 57(19) | 66(22) | 3(1) | ||
| Fosfomycin (n=300) | R(n=94) | 13(4) | 1(0.3) | 13(4) | 67(22) | 0 | 0.000 |
| S(n=206) | 107(36) | 2(0.6) | 68(23) | 18(6) | 11(4) | ||
| Neomycin (n=14) | R(n=4) | 0 | 0 | 1(7) | 3(21) | 0 | 0.435 |
| S(n=10) | 2(14) | 1(7) | 4(29) | 3(21) | 0 | ||
| Colistin (n=293) | R(n=13) | 2(0.6) | 3(1) | 1(0.3) | 7(2) | 0 | 0.000 |
| S(n=280) | 113(39) | 0 | 79(27) | 77(26) | 11(3) |
R=resistance, S= sensitivity.